pharma news today obesity drugs glp-1 september 2025 2024 was a record year for trials and is already poised to take over The GLP-1 trend: What the
Description
has received grant support from AstraZeneca, Eli Lilly, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and NovoNordisk
But we've got to go back to something because
Based on Eli Lilly's public statements and typical FDA timelines, retatrutide approval is most likely in late 2027 or early 2028
Am Heart Assoc 2009
Most are once-weekly or daily GLP-1 injectable pens, while Rybelsus is a daily tablet
